Press releases

19 July, 2024

Regulatory

Positive interim analysis in Abliva’s FALCON study triggers convertible loan conversion

Abliva AB (Nasdaq Stockholm: ABLI) a clinical-stage company developing medicines for the treatment of rare and severe primary mitochondrial disease, today announced that the convertible loan of SEK 42 ...

25 April, 2024

Regulatory

Abliva resolves on a directed issue of shares to guarantors in connection with the completed rights issue

Abliva AB (Nasdaq Stockholm: ABLI) ("Abliva" or the "Company") has today, based on the authorization from the extraordinary general meeting on 26 March 2024, resolved on a directed issue of 5,003,783 ...

19 April, 2024

Regulatory

Abliva publishes rights issue outcome

Abliva AB (Nasdaq Stockholm: ABLI) (”Abliva”) or the ”Company”) today announces that the new share issue with preferential rights for existing shareholders, announced by the Company on 22 February 202 ...

22 February, 2024

Regulatory

The Board of Directors of Abliva resolves on a fully guaranteed rights issue of SEK 46 million and a directed issue of convertible bonds of SEK 42 million to prepare for the final stage of the FALCON study

The Board of Directors of Abliva AB (publ) (Nasdaq Stockholm: ABLI) (“Abliva” or the “Company”) has today resolved on a capital raise totalling approximately SEK 88 million (the “Transaction”). The Tr ...

13 July, 2022

Regulatory

Last day of trading with BTA in Abliva

Abliva AB has carried out a rights issue where the subscription period ended June 27, 2022. The rights issue has been registered with the Swedish Companies Registration Office (Sw. Bolagsverket) and t ...

29 June, 2022

Regulatory

Abliva finishes SEK200M financing round with publication of rights issue outcome

1 June, 2022

Regulatory

Abliva decides on a SEK 200 million financing to fund Phase 2/3 study of KL1333 to interim analysis and bring in new global life science and institutional investors

The Board of Directors of Abliva AB (Nasdaq Stockholm: ABLI) (“Abliva” or the “Company”) has approved a directed issue of approximately SEK 150 million to several life science specialist and instituti ...

31 May, 202222 February, 2024

Regulatory

Abliva targets SEK 200 million raise to fund the KL1333 Phase 2/3 study to interim analysis

Abliva AB (Nasdaq Stockholm: ABLI) today announced that it intends to raise a financing round of SEK 200 million to provide the company with the capital necessary to run the Phase 2/3 study with KL133 ...

20 December, 2021

Regulatory

Abliva resolves on directed issue of convertibles amounting to SEK 26 million

The Board of Directors of Abliva AB (Nasdaq Stockholm: ABLI) (“Abliva” or “the Company”) has today resolved to issue convertibles corresponding to SEK 26 million, subject to the approval of an extraor ...

30 March, 2021

Regulatory

Abliva has completed a directed new issue

Abliva AB (Nasdaq Stockholm: ABLI) (“Abliva” or “the Company”), a biopharmaceutical company in the clinical phase that develops drugs for the treatment of rare and serious primary mitochondrial diseas ...

30 March, 2021

Regulatory

Abliva investigates the prerequisites for carrying out a directed new issue

Abliva AB (Nasdaq Stockholm: ABLI) (“Abliva” or the “Company”) a clinical-stage biopharmaceutical company developing medicines for the treatment of rare and severe primary mitochondrial diseases, toda ...

20 May, 2020

Last day of trading with BTA in NeuroVive

The rights issue in NeuroVive Pharmaceutical AB (publ) (“NeuroVive” or the “Company”) has today been registered with the Swedish Companies Registration Office (Sw. Bolagsverket) and paid subscribed sh ...